95 related articles for article (PubMed ID: 22704893)
41. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
Patel PR; Yoo S; Broadwater G; Marks LB; Miles EF; D'Amico TA; Harpole D; Kelsey CR
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):362-8. PubMed ID: 22516382
[TBL] [Abstract][Full Text] [Related]
42. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
43. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
Trafalis DT; Alifieris C; Krikelis D; Tzogkas N; Stathopoulos GP; Athanassiou AE; Sitaras NM
Int J Clin Pharmacol Ther; 2012 Jul; 50(7):490-9. PubMed ID: 22578202
[TBL] [Abstract][Full Text] [Related]
44. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
45. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
46. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.
Arrieta Ó; Medina LA; Estrada-Lobato E; Hernández-Pedro N; Villanueva-Rodríguez G; Martínez-Barrera L; Macedo EO; López-Rodríguez V; Motola-Kuba D; Corona-Cruz JF
Br J Cancer; 2012 Mar; 106(6):1027-32. PubMed ID: 22353806
[TBL] [Abstract][Full Text] [Related]
47. Malignant pleural mesothelioma in Singapore.
Yip CS; Koong HN; Loo CM; Fong KW
Asian Pac J Cancer Prev; 2011; 12(5):1155-9. PubMed ID: 21875258
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos D; Roda D; De Miguel Luken MJ; Petruckevitch A; Jalil A; Capelan M; Michalarea V; Lima J; Diamantis N; Bhosle J; Molife LR; Banerji U; de Bono JS; Popat S; O'Brien MER; Yap TA
Eur J Cancer; 2017 Apr; 75():56-62. PubMed ID: 28214659
[TBL] [Abstract][Full Text] [Related]
49. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.
Trovo M; Relevant A; Polesel J; Muraro E; Barresi L; Drigo A; Baresic T; Bearz A; Fanetti G; Del Conte A; Matrone F; Reverberi C; Furlan C; Zuccon U; Fontana P; Franchin G; Minatel E
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1368-1376. PubMed ID: 33259933
[TBL] [Abstract][Full Text] [Related]
50. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.
Vivoda Tomšič M; Korošec P; Kovač V; Bisdas S; Šurlan Popovič K
BMC Cancer; 2022 Feb; 22(1):191. PubMed ID: 35184730
[TBL] [Abstract][Full Text] [Related]
51. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.
Markowitz P; Patel M; Groisberg R; Aisner J; Jabbour SK; De S; Ganesan S; Malhotra J
Cancer Treat Res Commun; 2020; 25():100232. PubMed ID: 33166854
[TBL] [Abstract][Full Text] [Related]
52. Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.
Sandri A; Guerrera F; Roffinella M; Olivetti S; Costardi L; Oliaro A; Filosso PL; Lausi PO; Ruffini E
J Thorac Dis; 2016 Aug; 8(8):2121-7. PubMed ID: 27621868
[TBL] [Abstract][Full Text] [Related]
53. Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification.
Urso L; Silic-Benussi M; Boscolo A; Lorenzi M; Bonanno L; Lunardi F; Guarneri V; Calabrese F; Rea F; Conte P; Pasello G
Cytokine; 2021 Oct; 146():155622. PubMed ID: 34153874
[TBL] [Abstract][Full Text] [Related]
54. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.
Edwards JG; Abrams KR; Leverment JN; Spyt TJ; Waller DA; O'Byrne KJ
Thorax; 2000 Sep; 55(9):731-5. PubMed ID: 10950889
[TBL] [Abstract][Full Text] [Related]
55. Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response.
Rahouma M; Aziz H; Ghaly G; Kamel M; Loai I; Mohamed A
Asian Pac J Cancer Prev; 2017 Aug; 18(8):2073-2078. PubMed ID: 28843224
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.
Mandrekar SJ; An MW; Meyers J; Grothey A; Bogaerts J; Sargent DJ
J Clin Oncol; 2014 Mar; 32(8):841-50. PubMed ID: 24516033
[TBL] [Abstract][Full Text] [Related]
57. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.
Mori T; Tajima K; Hirama M; Sato T; Kido K; Iwakami S; Sasaki S; Iwase A; Shiomi K; Maeda M; Hino O; Takahashi K
J Thorac Dis; 2013 Apr; 5(2):145-8. PubMed ID: 23585940
[TBL] [Abstract][Full Text] [Related]
58. Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.
Kidd AC; McGettrick M; Tsim S; Halligan DL; Bylesjo M; Blyth KG
BMJ Open Respir Res; 2018; 5(1):e000240. PubMed ID: 29468073
[TBL] [Abstract][Full Text] [Related]
59. Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
Walter RF; Vollbrecht C; Werner R; Mairinger T; Schmeller J; Flom E; Wohlschlaeger J; Barbetakis N; Paliouras D; Chatzinikolaou F; Adamidis V; Tsakiridis K; Zarogoulidis P; Trakada G; Christoph DC; Schmid KW; Mairinger FD
J Cancer; 2016; 7(13):1915-1925. PubMed ID: 27698933
[TBL] [Abstract][Full Text] [Related]
60. Progression-free survival 2: Is it ready for prime time?
George B; Kurzrock R
Cancer; 2022 Apr; 128(7):1361-1362. PubMed ID: 34985767
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
